trending Market Intelligence /marketintelligence/en/news-insights/trending/ZO9nvcw_nrh3Ce_N0SsNgA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Natera, BGI Genomics collaborate to commercialize DNA test in China

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Natera, BGI Genomics collaborate to commercialize DNA test in China

San Carlos, Calif.-based diagnostic company Natera Inc. is partnering with Shenzhen-listed BGI Genomics Co. Ltd. to commercialize its custom tumor DNA test in China.

Under the 10-year agreement, Natera's Signatera custom tumor DNA test will initially be offered in China through a specialty hospital network. The test will be offered more broadly upon receipt of Chinese regulatory approval for use of Signatera on BGI Genomics' DNBseq next-generation sequencing technology platform.

The partnership also includes the development of reproductive health tests in select markets on BGI Genomics' sequencing instruments through the DNBseq platform.

Natera will receive $50 million in up-front licensing fees, prepaid royalties and future milestone payments from BGI Genomics. Meanwhile, Natera will prepay BGI Genomics $6 million for sequencing services related to the collaboration.

In September 2018, Bristol-Myers Squibb Co. agreed to use Signatera in a mid-stage study testing its blockbuster drug Opdivo as an additional therapy for patients with lung cancer. Additionally, Neon Therapeutics Inc. in October 2018 said it will use Signatera in an early-stage lung cancer trial evaluating a combination of its NT-002 drug and Merck & Co. Inc.'s Keytruda plus chemotherapy.